CAR-T– tag –
-
Exreprotein Launches Animal-Derived Component-Free Cell Culture Supplement for Immune and Stem Cell Research, Enhancing Consistency and Performance
Product information/Industry review Unknown Overview Exreprotein has introduced the 'Exreprotein Cell Culture Supplemental Mix,' an advanced formulation specifically designed for immune and stem cell research. This supplement is chemical... -
Northway Biotech Unveils €61M Personalized Medicine & CAR-T Manufacturing Plant in Lithuania, Accelerating European CGT Hub Formation
European Biotechnology Lithuania Overview CDMO Northway Biotech has invested €61 million to open a state-of-the-art cell therapy and personalized medicine center in Vilnius, Lithuania. The facility is actively pursuing GMP manufacturing ... -
Ori Biotech Secures $120M, 10-Year Partnership for Automated Cell Therapy Manufacturing; Vyriad’s In Vivo CAR-T Clears IND
RegMedNet UK Overview Ori Biotech announced a 10-year, $120 million partnership with an undisclosed biopharma firm to automate cell therapy manufacturing using its IRO platform, aiming to improve patient access. Concurrently, Vyriad secu... -
Tempest Therapeutics Licenses Senlang’s In Vivo CAR-T Platform, Targeting Relapsed/Refractory Multiple Myeloma with Dual BCMA/GPRC5D Approach in Phase I Trial
AllSci USA Overview Tempest Therapeutics has secured an exclusive license option for Hebei Senlang Biotechnology's CD7-targeting lentiviral in vivo CAR-T platform and related product candidates. This platform generates CAR-T and CAR-NK c... -
BioInformant Report Outlines 2026 iPSC-Derived Cell Therapeutic Pipeline, Highlighting Safety Challenges and Key Developers
BioInformant USA Overview This article provides an overview of a market research report by BioInformant, focusing on the 2026 pipeline for iPSC-derived cell therapeutics. The report analyzes the current state and future challenges, ident... -
GC Cell’s CAR-NK Therapy GCC2005 Approved for Compassionate Use in Refractory T-Cell Lymphoma at SNUH, South Korea
Korea Biomedical Review South Korea Overview GC Cell's CAR-NK cell therapy, GCC2005, has received approval for compassionate use in patients with refractory T-cell lymphoma at Seoul National University Hospital (SNUH) in South Korea. Thi... -
In Vivo CAR T-cell Generation Advances: VivoVec Platform Streamlines Manufacturing and Treatment Workflows, Reducing Lymphodepletion Dependence
Frontiers International Overview Advances in in vivo CAR T-cell generation, particularly platforms like VivoVec, show potential to simplify manufacturing and treatment workflows by enhancing CAR T-cell expansion and persistence. This app... -
Northway Biotech Opens Landmark €61M CDMO in Lithuania, Set to Drive European Cell and Personalized Medicine Manufacturing Scale-Up
chemanager-online.com Lithuania Overview Northway Biotech has launched a state-of-the-art €61 million Contract Development and Manufacturing Organization (CDMO) in Vilnius, Lithuania, specifically designed for cell therapy and personaliz... -
Drug Discovery News Highlights Rising Complexity in Biologics Manufacturing: Urges Manufacturability by Design, Raw Material Quality, and Process Intensification
Drug Discovery News USA Overview Drug Discovery News reports on the increasing complexity in manufacturing biologics, cell-based therapies (including CAR T), viral vectors, and oligonucleotides. The article identifies key challenges such... -
BubbleGen: Bracco Imaging’s Bead-Free Microbubble Technology Revolutionizes CAR-T Cell Selection
Manufacturing Chemist Italy Overview Bracco Imaging has launched its BubbleGen CD3+ T Cell Selection Kit, a pioneering bead-free technology set to transform CAR-T cell manufacturing. Leveraging gas-core, lipid-shell microbubbles for gent...
